CHURCHILL CAPITAL CORP-CL A
CCXINASDAQ🏆 #2972 by market capUS Equity
$12.24▲ $0.20 (+1.66%)
LiveTrack CCXI
Get earnings, price moves & breaking news on Telegram
24h▲ 1.7%
7d▼ 6.8%
14d▲ 1.7%
30d▼ 12.4%
ytd—
1y—
🏦Market Cap
$513M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair
Trading Snapshot
- Day Range
- $12.09 – $12.48
- 52-Week Range
- $10.07 – $19.69
- Volume
- $3.35B
- Avg Volume
- $4.22B
- Shares Outstanding
- 41.9M
- Next Earnings
- Nov 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $165M
- Last Q Revenue
- $45M
- P/E Ratio
- -5.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.41
- Dividend Yield
- 0.00%
Why Investors Own CCXI
- ✓High-growth profile — revenue up +2.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CHURCHILL CAPITAL CORP-CL A
CCXIFinancial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$165M▲ +4.9% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
42.5%▲ +2.5% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$56M▲ +4.9% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$29M▲ +4.9% YoY
StockOtter · stockotter.spaceAbout CHURCHILL CAPITAL CORP-CL A
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100
Analyst Ratings
ⓘConsensus
Hold
13 analysts
Strong Buy0
Buy0
Hold10
Sell1
Strong Sell2
Ratings as of Oct 2022
Latest News & Updates
🚀
CNBC·2h ago
CHURCHILL CAPITAL CORP-CL A tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift CCXI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
CHURCHILL CAPITAL CORP-CL A announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.